USDA’s arbitrary rules about what is permitted for the “organic” designation prohibit important advances in agriculture and food production, and they unnecessarily restrict consumer choice. That could be remedied by expanding what is permitted under the federal National Organic Standards, and this would be an opportune time.

On Friday President Trump in the White House Rose Garden briefly outlined the four key aspirational strategies of his "blueprint to lower drug prices": "improved competition, better negotiation, incentives for lower list prices, and lowering out-of-pocket costs."

Dogs bark, cows moo, and regulators regulate,” former U.S. Food and Drug Administration commissioner Frank Young once quipped to explain regulatory agencies’ expansionist tendencies. There may be no better example than the FDA’s oversight of genetically engineered animals.

Occasionally we encounter a simple tweak in public policy that would be a win-win -— if it weren’t for politicians, bureaucrats and stakeholders zealously guarding their self-interest. An example is a reform that would both help combat shortages of critical drugs and put downward pressure on prices: reciprocity of drug approvals between FDA and certain foreign counterparts.